TVTX(Travere Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $131.84M | $109.46M | $145.24M | $233.18M | $490.73M |
| 毛利润 | $128.02M | $105.04M | $133.79M | $225.43M | $480.39M |
| 营业利润 | −$199.43M | −$319.81M | −$388.14M | −$323.83M | −$62.82M |
| 净利润 | −$180.09M | −$278.48M | −$111.40M | −$321.55M | −$25.55M |
| 经营现金流 | −$14.79M | −$186.29M | −$280.02M | −$237.47M | $37.78M |
| 自由现金流 | −$19.89M | −$186.48M | −$280.69M | — | — |
| 摊薄每股收益 | $-3.01 | $-4.37 | $-1.50 | $-4.08 | $-0.29 |